

## FOI Request re. Number of Patients Treated

Please note the following:

We are unable to provide some of the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers of drugs used, for Questions 1,3 and 6, therefore as these totals affect the outcome of the answers for questions 2 and 5, they too have had the figures banded.

*This exemption is an absolute exemption and therefore no consideration of the public interest test is needed.*

1. How many patients were treated within your Trust with the following drugs within the specified time periods?

Drug	Number of patients treated between 01 February 2017 and 31 July 2018	Number of patients treated between 01 August 2018 and 31 January 2020
Apremilast	24	5
Adalimumab	394	435
Dupilumab	0	25
Etanercept	<5	<5
Infliximab	175	159
Secukinumab	30	44
Ustekinumab	84	117

2. How many patients were treated within your Trust for atopic dermatitis within the specified time periods?

Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
700 -720 patients	780-795 patients

3. How many patients were treated within your Trust with the following drugs for atopic dermatitis within the specified time periods?

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast	24	<5
Adalimumab	71	87
Dupilumab	0	25
Etanercept	<5	<5
Infliximab	0	0
Secukinumab	30	44
Ustekinumab	55	51

4. Please specify how patients treated with the following drugs are coded (OPCS code) within your Trust:

Drug	OPCS code (e.g. X385 subcutaneous immunotherapy)
Apremilast	X92.1
Adalimumab	X92.1
Dupilumab	X38.4
Etanercept	X92.1
Infliximab	X92.1
Secukinumab	X92.1
Ustekinumab	X89.1

Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:

- 5.

Number of patients treated in the homecare setting for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated in the homecare setting for atopic dermatitis between 01 August 2018 and 31 January 2020
150-160 patients	205-210patients

6. How many of your Trust's homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?

Drug	Number of patients treated for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated for atopic dermatitis between 01 August 2018 and 31 January 2020
Apremilast	0	0
Adalimumab	71	87
Dupilumab	0	25
Etanercept	<5	<5
Infliximab	0	0
Secukinumab	29	44
Ustekinumab	55	51